Innovations in bioprocessing, formulation & stability of vaccines are redefining how vaccines are manufactured, preserved, and delivered globally. From cell culture optimization to downstream purification, every stage of vaccine production demands precision and consistency. Stabilizing agents and novel excipients are being integrated to extend shelf life and maintain potency in diverse storage conditions, particularly important for low-resource settings. Lyophilization, microencapsulation, and thermostable formulations are among the promising strategies ensuring stability without relying on cold chain infrastructure. Quality by design (QbD) principles and real-time monitoring technologies are also helping manufacturers maintain rigorous standards. As vaccine technologies evolve rapidly, optimizing bioprocessing, formulation & stability of vaccines is critical for cost-effective, scalable, and equitable immunization programs worldwide.
Khursheed Anwer
IMUNON, United States
Ping Xie
Rutgers University, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Lara Isis Teodoro
Mayo Clinic, United States
Ahmed Abdulazeez
BHRUT Trust, United Kingdom
Elena Chiappini
University of Florence, Italy
Ayesha Zahid
Griffith University, Australia
Livia Daflon Silva
Federal University of State of Rio de Janeiro, Brazil
Neha Bhandari
Chitkara University, IndiaSubmit your abstract Today
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States